复旦张江(688505) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 189,147,552, representing a year-on-year increase of 34.33%[5] - The net profit attributable to shareholders for the same period was CNY 8,787,158, reflecting a significant increase of 78.39% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 252.85% to CNY 2,349,656[5] - Total operating revenue for Q1 2023 reached ¥189,147,552, a 34.3% increase from ¥140,805,956 in Q1 2022[17] - Net profit for Q1 2023 was ¥8,794,123, compared to a net profit of ¥4,810,020 in Q1 2022, representing a 83.5% increase[18] - The total comprehensive income for Q1 2023 was ¥8,449,017, compared to ¥4,347,867 in Q1 2022, marking a 94.5% increase[19] Research and Development - Research and development expenses totaled CNY 54,511,436, accounting for 28.82% of operating revenue, a decrease of 6.49 percentage points compared to the previous year[6] - Research and development expenses were ¥54,123,028, an increase of 11.0% from ¥48,439,435 in the same period last year[17] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,850,342,292, down 4.22% from the end of the previous year[6] - As of March 31, 2023, the total assets of Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. amounted to CNY 2,850,342,292, a decrease from CNY 2,976,007,272 at the end of 2022[13] - The company's current assets decreased to CNY 1,863,871,518 from CNY 2,069,188,785, reflecting a decline of approximately 9.94%[13] - The total liabilities decreased to CNY 588,372,864 from CNY 722,985,917, representing a reduction of approximately 18.6%[15] - The company's equity attributable to shareholders increased slightly to CNY 2,266,043,325 from CNY 2,257,102,217, showing a growth of about 0.35%[15] - The company reported a decrease in non-current liabilities to CNY 45,699,858 from CNY 49,641,713, a decline of approximately 7.4%[15] Cash Flow - The net cash flow from operating activities was negative at CNY -160,260,214, primarily due to payments made for accounts payable from the previous year[8] - Cash flow from operating activities totaled ¥162,901,241, down from ¥200,904,381 in Q1 2022, indicating a decrease of 18.9%[21] - The net cash flow from operating activities was -$160.26 million, compared to -$17.21 million in the previous period, indicating a significant increase in cash outflow[23] - The net increase in cash and cash equivalents for the first quarter was -$401.29 million, compared to -$59.13 million in the previous year[24] - The ending balance of cash and cash equivalents was $888.01 million, down from $1.15 billion at the end of the previous period[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,986[10] - Major shareholders included HKSCC NOMINEES LIMITED with 22.24% ownership and Shanghai Pharmaceutical Group with 20.42% ownership[10] - The number of shareholders as of the report date was 21,986, with 21,849 holding A shares and 137 holding H shares[11] Other Information - The company reported non-recurring gains of CNY 6,437,502, which included government subsidies and asset disposal gains[7] - The company has not disclosed any significant new strategies or product developments in the current report[12] - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting[24] - The cash flow from operating activities reflects challenges in generating positive cash flow, which may impact future operational strategies[23] - The company continues to monitor its cash position closely amid fluctuating cash flows from various activities[24]